David Young - 27 Jan 2025 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
27 Jan 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
18 Feb 2025, 17:57:28 UTC
Date Of Original Report
29 Jan 2025
Previous filing
02 Aug 2024
Next filing
11 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCSA Common Stock 205,405 27 Jan 2025 Direct
holding PCSA Common Stock 30,985 27 Jan 2025 By Young-Plaisance Revocable Trust
holding PCSA Common Stock 10,786 27 Jan 2025 By Family Entities
holding PCSA Common Stock 18,544 27 Jan 2025 By CorLyst, LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Warrants Award $0 +124,500 $0.000000 124,500 29 Jan 2025 Common Stock 124,500 $0.6500 Direct
transaction PCSA Warrants Award $0 +62,250 $0.000000 62,250 29 Jan 2025 Common Stock 62,250 $0.6500 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.